NASDAQ:RDHL RedHill Biopharma (RDHL) Stock Forecast, Price & News $0.51 -0.07 (-12.07%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$0.50▼$0.5750-Day Range$0.51▼$1.3652-Week Range$0.50▼$38.40Volume329,515 shsAverage Volume223,326 shsMarket Capitalization$2.98 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media About RedHill Biopharma (NASDAQ:RDHL) StockRedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.Read More RDHL Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RDHL Stock News HeadlinesSeptember 22, 2023 | americanbankingnews.comRedHill Biopharma (NASDAQ:RDHL) Shares Cross Below 200 Day Moving Average of $2.36September 5, 2023 | finance.yahoo.comRedHill Announces New USPTO Notice of Patent Allowance for Opaganib and EU Patent Grant for RHB-102 (BEKINDA®)September 29, 2023 | Weiss Ratings (Ad)Overlooked AI Stock Gets Urgent "Buy"We issued our first "Buy" rating on Apple when it traded at the equivalent of 56 cents per share. It's up 32,571% since. And while Nvidia is up 3x this year… We called it back in 2011. And it has surged 97x (9,624% to be exact) since then. Now, our Weiss Ratings has issued a "Buy" on a stock that's leading the AI revolution in one of the most profitable industries.August 17, 2023 | finance.yahoo.comRedHill Biopharma Provides H1/23 Financial Results and Operational HighlightsJuly 31, 2023 | finance.yahoo.comRedHill's RHB-107 Included in U.S. Government-Supported COVID-19 Platform Trial and Cleared for Initiation by FDAJuly 25, 2023 | finance.yahoo.comRedHill Biopharma Announces Closing of $3.8 Million Registered Direct Offering and Warrant ExerciseJuly 21, 2023 | benzinga.comWhat's Going On With RedHill Biopharma Stock TodayJuly 21, 2023 | finance.yahoo.comRedHill Biopharma Announces Registered Direct Offering and Warrant Exercise for $3.8 Million Gross ProceedsSeptember 29, 2023 | Porter and Company (Ad)The Elites Are Waging War on Elon Musk — Here's Why…Elon has helped unleash an opportunity that could create trillions in wealth for everyday Americans. So why does the deep state hate him for it?July 21, 2023 | finance.yahoo.comRedHill Announces Additional U.S. Government Funding for Opaganib Nuclear Countermeasure DevelopmentJuly 6, 2023 | technews.tmcnet.comPhil and RedHill Biopharma Partner to Increase Access to Talicia®June 12, 2023 | finanznachrichten.deRedHill Biopharma Ltd.: RedHill Biopharma Announces Q1/2023 Financial Results and Operational HighlightsJune 12, 2023 | finance.yahoo.comRedHill Biopharma Announces Q1/2023 Financial Results and Operational HighlightsMay 24, 2023 | bizjournals.comRaleigh drug developer trims R&D pipeline, shifts resourcesMay 22, 2023 | finance.yahoo.comRedHill Provides R&D UpdateMay 15, 2023 | finance.yahoo.comRedHill Biopharma Receives NASDAQ Notification Regarding Minimum Market Value of Publicly Held Shares DeficiencyMay 9, 2023 | finance.yahoo.comRedHill Publishes New Talicia® Data on Generic Non-Bioequivalence in AP&T and Presents New Dosing Data at Digestive Disease WeekMay 1, 2023 | finance.yahoo.comRedHill's RHB-102 (BEKINDA®) and Opaganib Granted New Patents in Oncology SettingApril 28, 2023 | finanznachrichten.deRedHill Biopharma Ltd.: RedHill Biopharma Announces Q4/22 & Full-Year 2022 Results and Operational HighlightsApril 28, 2023 | finance.yahoo.comRedHill Biopharma Announces Q4/22 & Full-Year 2022 Results and Operational HighlightsApril 17, 2023 | finance.yahoo.comBenign Growth For RedHill Biopharma Ltd. (NASDAQ:RDHL) Underpins Stock's 41% PlummetApril 11, 2023 | finance.yahoo.comRedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price RequirementApril 3, 2023 | finance.yahoo.comRedHill Biopharma Announces Closing of $6 Million Registered Direct OfferingMarch 30, 2023 | finance.yahoo.comRedHill Biopharma Announces $6 Million Registered Direct OfferingMarch 23, 2023 | finance.yahoo.comRedHill Biopharma Ltd.'s (NASDAQ:RDHL) market cap dropped US$146m last week; Individual investors bore the bruntMarch 23, 2023 | finanznachrichten.deRedHill Biopharma Ltd: RedHill Biopharma Announces Plan to Implement ADS Ratio ChangeMarch 21, 2023 | finance.yahoo.comRedHill Initiates First Community-Setting Warranty Program to Refund Talicia Non-RespondersSee More Headlines Receive RDHL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RedHill Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address RDHL Company Calendar Last Earnings8/17/2023Today9/29/2023Next Earnings (Estimated)12/05/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RDHL CUSIPN/A CIK1553846 Webwww.redhillbio.com Phone972-3541-3131Fax972-3541-3144Employees113Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-71,670,000.00 Net Margins354.95% Pretax Margin-9.10% Return on Equity-328.99% Return on Assets71.39% Debt Debt-to-Equity RatioN/A Current Ratio0.96 Quick Ratio0.78 Sales & Book Value Annual Sales$61.80 million Price / Sales0.05 Cash FlowN/A Price / Cash FlowN/A Book Value($16.41) per share Price / Book-0.03Miscellaneous Outstanding Shares5,850,000Free Float5,455,000Market Cap$2.98 million OptionableOptionable Beta2.00 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Dror Ben-Asher (Age 57)Co-Founder, CEO & Director Comp: $734.59kMr. Gilead Raday MPhil (Age 48)MSc, Chief Operating Officer Comp: $445.38kMr. Adi Frish (Age 53)Chief Corp. & Bus. Devel. Officer Comp: $419.5kMr. Rick D. Scruggs (Age 63)Chief Commercial Officer, Pres of RedHill Biopharma Inc. & Director Comp: $607.05kMr. Razi Ingber (Age 39)Chief Financial Officer Ms. Alexandra OkmianSr. Bus. Devel. & Investor Relations Mang.Dr. Reza Fathi Ph.D. (Age 68)Sr. VP of R&D Mr. Guy Goldberg (Age 47)Chief Bus. Officer Dr. June S. Almenoff F.A.C.P. (Age 66)M.D., Ph.D., Chief Medical Officer Ms. Patricia Anderson B.Sc. RACSr. VP of Regulatory AffairsMore ExecutivesKey CompetitorsPanbela TherapeuticsNASDAQ:PBLAABVC BioPharmaNASDAQ:ABVCAdial PharmaceuticalsNASDAQ:ADILSynaptogenixNASDAQ:SNPX60 Degrees PharmaceuticalsNASDAQ:SXTPView All CompetitorsInstitutional OwnershipCowen AND Company LLCBought 288,000 shares on 8/7/2023Ownership: 7.328%View All Institutional Transactions RDHL Stock - Frequently Asked Questions How have RDHL shares performed in 2023? RedHill Biopharma's stock was trading at $5.6120 at the beginning of 2023. Since then, RDHL shares have decreased by 90.9% and is now trading at $0.51. View the best growth stocks for 2023 here. Are investors shorting RedHill Biopharma? RedHill Biopharma saw a drop in short interest in September. As of September 15th, there was short interest totaling 5,600 shares, a drop of 27.3% from the August 31st total of 7,700 shares. Based on an average daily volume of 393,700 shares, the short-interest ratio is presently 0.0 days. Currently, 0.1% of the shares of the company are short sold. View RedHill Biopharma's Short Interest. When is RedHill Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, December 5th 2023. View our RDHL earnings forecast. How were RedHill Biopharma's earnings last quarter? RedHill Biopharma Ltd. (NASDAQ:RDHL) announced its earnings results on Thursday, August, 17th. The biotechnology company reported $36.00 earnings per share (EPS) for the quarter. The biotechnology company earned $1.80 million during the quarter. RedHill Biopharma had a net margin of 354.95% and a negative trailing twelve-month return on equity of 328.99%. When did RedHill Biopharma's stock split? RedHill Biopharma's stock reverse split on the morning of Thursday, March 23rd 2023. The 1-40 reverse split was announced on Thursday, March 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of RedHill Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other RedHill Biopharma investors own include Agenus (AGEN), Sorrento Therapeutics (SRNE), Sangamo Therapeutics (SGMO), Verastem (VSTM), Amarin (AMRN), Aralez Pharmaceuticals (ARLZ), Inovio Pharmaceuticals (INO), Tesla (TSLA), Gilead Sciences (GILD) and NVIDIA (NVDA). What is RedHill Biopharma's stock symbol? RedHill Biopharma trades on the NASDAQ under the ticker symbol "RDHL." How do I buy shares of RedHill Biopharma? Shares of RDHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is RedHill Biopharma's stock price today? One share of RDHL stock can currently be purchased for approximately $0.51. How much money does RedHill Biopharma make? RedHill Biopharma (NASDAQ:RDHL) has a market capitalization of $2.98 million and generates $61.80 million in revenue each year. How many employees does RedHill Biopharma have? The company employs 113 workers across the globe. How can I contact RedHill Biopharma? RedHill Biopharma's mailing address is 21 Ha'arba'a Street, Tel Aviv L3, 64739. The official website for the company is www.redhillbio.com. The biotechnology company can be reached via phone at 972-3541-3131, via email at investors@redhillbio.com, or via fax at 972-3541-3144. This page (NASDAQ:RDHL) was last updated on 9/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RedHill Biopharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.